Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study

NCT01237327 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01237327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01237327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2001
Completion date
December 31, 2009
Enrollment
84 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer